{
    "ticker": "OVID",
    "name": "Ovid Therapeutics Inc.",
    "description": "Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapies for patients with rare neurological diseases. Founded in 2014 and headquartered in New York, Ovid focuses on leveraging its expertise in neuroscience to create targeted treatments that address unmet medical needs. The company\u2019s lead product candidates, including OV101 and OV935, are designed to treat conditions such as Angelman syndrome and other neurodevelopmental disorders. Ovid is committed to advancing science and improving the lives of patients through research and collaboration with the scientific community. The company actively seeks to engage with patients and their families, ensuring that their voices are heard in the drug development process. With a robust pipeline and a passion for innovation, Ovid is at the forefront of transforming how rare neurological conditions are treated, aiming to provide hope and improved quality of life for those affected.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2014",
    "website": "https://www.ovidrx.com",
    "ceo": "Jeremy Tarchini",
    "social_media": {
        "twitter": "https://twitter.com/OvidRx",
        "linkedin": "https://www.linkedin.com/company/ovid-therapeutics/"
    },
    "investor_relations": "https://www.ovidrx.com/investors",
    "key_executives": [
        {
            "name": "Jeremy Tarchini",
            "position": "CEO"
        },
        {
            "name": "Alison N. W. D. K. S. N. K. B. N. T. E. J. B. W. T. S.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Development",
            "products": [
                "OV101",
                "OV935"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ovid Therapeutics Inc. | Innovative Therapies for Neurological Disorders",
        "meta_description": "Explore Ovid Therapeutics Inc., a leader in developing therapies for rare neurological diseases. Learn about Ovid's mission, pipeline, and commitment to patient care.",
        "keywords": [
            "Ovid Therapeutics",
            "Neurological Disorders",
            "Biopharmaceuticals",
            "Angelman Syndrome",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does Ovid Therapeutics focus on?",
            "answer": "Ovid Therapeutics focuses on developing innovative therapies for rare neurological diseases."
        },
        {
            "question": "Who is the CEO of Ovid Therapeutics?",
            "answer": "Jeremy Tarchini is the CEO of Ovid Therapeutics Inc."
        },
        {
            "question": "Where is Ovid Therapeutics headquartered?",
            "answer": "Ovid Therapeutics is headquartered in New York, New York, USA."
        },
        {
            "question": "What are Ovid's main product candidates?",
            "answer": "Ovid's main product candidates include OV101 and OV935, targeting conditions like Angelman syndrome."
        },
        {
            "question": "When was Ovid Therapeutics founded?",
            "answer": "Ovid Therapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "SAGE",
        "ALNY",
        "RGEN",
        "VRTX"
    ],
    "related_stocks": [
        "BIIB",
        "AMGN",
        "GILD",
        "NVS"
    ]
}